Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer

SpringerPlus

Volumn 2, Issue 1, 2013, Pages 1-7

  Bhatta, Sumita S ^a   Hou, Ningqi ^a   Moton, Zakiya N ^a   Polite, Blase N ^a   Fleming, Gini F ^a   Olopade, Olufunmilayo I ^a   Huo, Dezheng ^a   Hong, Susan ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adjuvant hormone therapy; Breast cancer; Healthcare disparities; Medication compliance

Indexed keywords

EID: 84887280709     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-356     Document Type: Article

References (30)

1. Barron TI, Connolly R, Bennett K, et al. (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109:832-839.
2. Bultman DC, Svarstad BL (2000) Effects of physician communication style on client medication beliefs and adherence with antidepressant treatment. Patient Educ Couns 40:173-185.
3. Cluze C, Rey D, Huiart L, et al. (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23:882-890.
4. Davies C, Godwin J, Gray R, et al. (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patientlevel meta-analysis of randomised trials. Lancet 378:771-784.
5. Davies C, Pan H, Godwin J, et al. (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816.
6. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322-328.
7. Fink AK, Gurwitz J, Rakowski W, et al. (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309-3315.
8. Font R, Espinas JA, Gil-Gil M, et al. (2012) Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in catalonia, spain. Br J Cancer 107:1249-1256.
9. Gray RG, Rea D, Handley K, et al. (2013) aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31. suppl;abstr 5.
10. Grunfeld EA, Hunter MS, Sikka P, et al. (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97-102.
11. Hershman DL, Unger JM, Barlow WE, et al. (2009) Treatment quality and outcomes of African American versus White breast cancer patients: Retrospective analysis of southwest oncology studies s8814/s8897. J Clin Oncol 27:2157-2162.
12. Hershman DL, Shao T, Kushi LH, et al. (2011) Early discontinuation and nonadherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537.
13. Horne R, Weinman J (1999) Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555-567.
14. Kahn KL, Schneider EC, Malin JL, et al. (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Medical Care 45:431-439.
15. Kaplan SH, Greenfield S, Ware JE, Jr (1989) Assessing the effects of physicianpatient interactions on the outcomes of chronic disease. Medical Care 27: S110-S127.
16. Kim SH, Ferrante J, Won BR, et al. (2008) Barriers to adequate follow-up during adjuvant therapy may be important factors in the worse outcome for black women after breast cancer treatment. World J Surg Oncol 6:26.
17. Kimmick G, Anderson R, Camacho F, et al. (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27:3445-3451.
18. Kirk MC, Hudis CA (2008) Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 8:155-161.
19. Kucukarslan SN (2012) A review of published studies of patients' illness perceptions and medication adherence: lessons learned and future directions. Res Social Adm Pharm 8:371-382.
20. Lash TL, Fox MP, Westrup JL, et al. (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215-220.
21. McGinnis B, Olson KL, Magid D, et al. (2007) Factors related to adherence to statin therapy. Ann Pharmacother 41:1805-1811.
22. Molfenter TD, Bhattacharya A, Gustafson DH (2012) The roles of past behavior and health beliefs in predicting medication adherence to a statin regimen. Patient Preference and Adherence 6:643-651.
23. Murphy CC, Bartholomew LK, Carpentier MY, et al. (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134:459-478.
24. Neugut AI, Hillyer GC, Kushi LH, et al. (2012) The breast cancer quality of care study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy. Breast J 18:203-213.
25. Patridge A (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602-606.
26. Pellegrini I, Sarradon-Eck A, Soussan PB, et al. (2010) Women's Perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view. Psychooncology 19:472-479.
27. Shelton RC, Hillyer GC, Hershman DL, et al. (2013) Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the bqual study. Breast Cancer Res Treat 137:817-828.
28. Stavropoulou C (2011) Non-adherence to medication and doctor-patient relationship: evidence from a european survey. Patient Educ Couns 83:7-13.
29. Thewes B, Meiser B, Duric VM, et al. (2005) What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 6:581-588.
30. Yu KD, Zhou Y, Liu GY, et al. (2012) A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat 134:307-313.